Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to 1.43%.

  • Ptc Therapeutics' EBITDA Margin rose 291300.0% to 1.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 43.61%, marking a year-over-year increase of 624300.0%. This contributed to the annual value of 37.5% for FY2024, which is 93600.0% up from last year.
  • As of Q3 2025, Ptc Therapeutics' EBITDA Margin stood at 1.43%, which was up 291300.0% from 19.54% recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' EBITDA Margin registered a high of 82.5% during Q1 2025, and its lowest value of 119.67% during Q4 2022.
  • In the last 5 years, Ptc Therapeutics' EBITDA Margin had a median value of 54.58% in 2022 and averaged 45.65%.
  • Per our database at Business Quant, Ptc Therapeutics' EBITDA Margin surged by 1644900bps in 2021 and then tumbled by -780700bps in 2024.
  • Quarter analysis of 5 years shows Ptc Therapeutics' EBITDA Margin stood at 51.28% in 2021, then plummeted by -133bps to 119.67% in 2022, then skyrocketed by 102bps to 1.9% in 2023, then tumbled by -4119bps to 76.18% in 2024, then soared by 102bps to 1.43% in 2025.
  • Its EBITDA Margin was 1.43% in Q3 2025, compared to 19.54% in Q2 2025 and 82.5% in Q1 2025.